CPL304110 is an Orally Active and Selective FGFR(1-3) Inhibitor

Over the last decade, the FGFRs family has become an attractive validated therapeutic target notably in cancer. It consists of four members (FGFR1 to FGFR4) which are structurally related cell surface RTKs. This FGF-FGFR axis participates in key biological processes that play significant roles in cell functions such as proliferation, growth, apoptosis, and differentiation. To date, considerable efforts have been focused on the development of small-molecule inhibitors targeting FGF/FGFR signaling in tumorigenesis. In this study, scientists focus on the group of small molecule inhibitors, TKI258, AZD2171, and PD173047, the first non-selective generation of FGFR TKIs which bind to the conserved ATP-binding domain in RTKs. Notwithstanding, this group has been used to treat several types of solid tumors such as breast cancers, squamous cell lung cancers, metastatic urothelial cancers, intrahepatic cholangiocarcinoma, but the benefits from clinical trials were fairly variable.

To overcome these drawbacks, scientists have developed a second generation of inhibitors of 2 pan-FGFR TKIs such as AZD4547 and CH5183284. Coincidentally, scientists discovered a candidate 56q (CPL304110).

CPL304110 is an Orally Active and Selective FGFR1 3 Inhibitor 2020 01 06 - CPL304110 is an Orally Active and Selective FGFR(1-3) Inhibitor

CPL304110 is a potent, orally active, and selective inhibitor of fibroblast growth factor receptors FGFR (1-3). It exhibits IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.

In vitro, CPL304110 (0-0.6 μM) dose-dependently inhibits FGFR2 phosphorylation and downstream signaling (p-ERK). Moreover, CPL304110 (compound 56q) exhibits an SNU-16 proliferation assay with an IC50 of 85.64 nM. Additionally, CPL304110 (compound 56q) demonstrates a more than 45-fold, 345-fold, 395-fold, and 680-fold selectivity over KDR (VEGFR2), Flt3, Aura A, and PDGFRb, respectively relative to FGFR2, and no significant inhibitory effects were observed with other tyrosine kinases.

In vivo, CPL304110 (p.o., 40 mg/kg) exhibits a t1/2 of 2 h and Cmax of 3369 ng/mL in mice. It also significantly inhibits tumor growth in mice without significant body loss or any toxicity.

Reference:

Abdellah Yamani, et al. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3). Eur J Med Chem. 2020 Nov 7;112990.

 

Tags:, ,